Systemic lupus erythematosus is a chronic, multisystem, inflammatory, autoimmune disorder characterized by formation of autoantibodies directed against self-antigens and immune-complex formation.
It can be diagnosed with a single organ involvement such as lupus nephritis.
It is predominantly diagnosed in females of childbearing age.
Clinical presentation varies in different patients and the disease activity varies over time in a single patient. Majority of patients have arthralgia of the hand.
In systemic lupus erythematosus (SLE) patients treated with hydroxychloroquine (HCQ), longer duration of use and higher cumulative dose, as well as lower creatinine clearance and geographical origin from sub-Saharan Africa and West Indies, appear to be associated with an increased risk of treatment-related retinopathy, as reported in a study.
In the treatment of active systemic lupus erythematosus (SLE), early administration of belimumab especially in patients with low damage at baseline is likely to lead to remission and low-disease activity (LDA), according to real-world data.
The type I interferon receptor subunit 1 mAb* anifrolumab significantly improves response in patients with systemic lupus erythematosus (SLE) in the second phase III randomized trial of the drug, TULIP-2** — in contrast to the first trial.
Use of ustekinumab in the treatment of systemic lupus erythematosus leads to significant improvements in many of the efficacy indices evaluated, with lower risk of flares and sustained response rates, when compared with placebo, according to 1-year data from a phase II trial.
Among Filipino patients with systemic lupus erythematosus (SLE), the use of immunosuppressive and corticosteroid contributes to an increased risk of developing herpes zoster infection, a study has found. The risk is even higher in lupus nephritis patients exposed to intravenous cyclophosphamide and mycophenolate mofetil.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.